Intensity Therapeutics (INTS) announced that INT230-6 achieved complete responses in a murine models of Malignant Peripheral Nerve Sheath Tumor. In a study, at 21 days, animals tested with INT230-6 all achieved a complete response, whereas all animals' tumors in the control group continued to grow.
"MPNST is the first neurological-specific tumor for which INT230-6 has been used. We are pleased to see that INT230-6 achieved meaningful results in MPMNST that are similar to the results we saw in other in vivo models where INT230-6 has been tested," said Lewis Bender, President and CEO of Intensity.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.